Naturally occurring resistance-associated variants of hepatitis C virus protease inhibitors in poor responders to pegylated interferon-ribavirin

Journal of Clinical Microbiology

Volumn 53, Issue 7, 2015, Pages 2195-2202

  Larrat, Sylvie ^a,b   Vallet, Sophie ^b,c   David Tchouda, Sandra ^a   Caporossi, Alban ^a,b   Margier, Jennifer ^a   Ramière, Christophe ^d   Scholtes, Caroline ^d   Haïm Boukobza, Stéphanie ^e,f   Roque Afonso, Anne Marie ^e,f   Besse, Bernard ^g   André Garnier, Elisabeth ^g   Mohamed, Sofiane ^b   Halfon, Philippe ^b   Pivert, Adeline ^b   LeGuillou Guillemette, Hélène ^b   Abravanel, Florence ^h   Guivarch, Matthieu ^h   Mackiewicz, Vincent ^b   Lada, Olivier ^b   Mourez, Thomas ⁱ   Plantier, Jean Christophe ⁱ   Baazia, Yazid ^b   Alain, Sophie ^j   Hantz, Sebastien ^j   Thibault, Vincent ^k   Gaudy Graffin, Catherine ^l   Bouvet, Dorine ^l   Mirand, Audrey ^m   Henquell, Cécile ^m   Gozlan, Joel ⁿ   Lagathu, Gisèle ^o   Pronier, Charlotte ^o   Velay, Aurélie ^p   Schvoerer, Evelyne ^p   Trimoulet, Pascale ^b   Fleury, Hervé ^b   Bouvier Alias, Magali ^q   Brochot, Etienne ^b   Duverlie, Gilles ^b   Maylin, Sarah ^r   Gouriou, Stéphanie ^a   Pawlotsky, Jean Michel ^q   Moranda, Patrice ^a,b   more..

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE BREST   (France)

^c BREST UNIVERSITY HOSPITAL   (France)

^d CROIX ROUSSE HOSPITAL   (France)

^e HÔPITAL PAUL BROUSSE   (France)

^f INSERM   (France)

^g HÔTEL DIEU   (France)

^h TOULOUSE UNIVERSITY HOSPITAL   (France)

ⁱ HÔPITAL CHARLES NICOLLE   (France)

^j DUPUYTREN UNIVERSITY HOSPITAL   (France)

^k PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^l UNIVERSITY HOSPITAL OF TOURS   (France)

^m UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

ⁿ HÔPITAL SAINT ANTOINE   (France)

^o RENNES UNIVERSITY HOSPITAL   (France)

^p UNIVERSITY HOSPITAL OF NANCY   (France)

^q HENRI MONDOR HOSPITAL   (France)

^r SAINT LOUIS HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; NONSTRUCTURAL PROTEIN 3; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; NS3 PROTEIN, HEPATITIS C VIRUS; OLIGOPEPTIDE; PROLINE; VIRAL PROTEIN;

ADULT; ALGORITHM; ANTIVIRAL RESISTANCE; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FIBROSIS; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); MUTATIONAL ANALYSIS; NONHUMAN; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEQUENCE ANALYSIS; VIRUS LOAD; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; IC50; ISOLATION AND PURIFICATION; MIDDLE AGED; MISSENSE MUTATION; MULTICENTER STUDY; TREATMENT OUTCOME; VIROLOGY;

HEPATITIS C VIRUS;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INHIBITORY CONCENTRATION 50; INTERFERON-ALPHA; MALE; MIDDLE AGED; MUTATION, MISSENSE; OLIGOPEPTIDES; PROLINE; PROTEASE INHIBITORS; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84932620949     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.03633-14     Document Type: Article

References (26)

1. Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, Lee B, Heckerman D, Carlson J, Reyor LL, Kleyman M, McMahon CM, Birch C, Schulze Zur Wiesch J, Ledlie T, Koehrsen M, Kodira C, Roberts AD, Lauer GM, Rosen HR, Bihl F, Cerny A, Spengler U, Liu Z, Kim AY, Xing Y, Schneidewind A, Madey MA, Fleckenstein JF, Park VM, Galagan JE, Nusbaum C, Walker BD, Lake-Bakaar GV, Daar ES, Jacobson IM, Gomperts ED, Edlin BR, Donfield SM, Chung RT, Talal AH, Marion T, Birren BW, Henn MR, Allen TM. 2008. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 48:1769-1778. http://dx.doi.org/10.1002/hep.22549.
2. Pawlotsky JM. 2014. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 146:1176-1192. http://dx.doi.org/10.1053/j.gastro.2014.03.003.
3. Pawlotsky JM. 2014. New hepatitis C therapies. Semin Liver Dis 34:7-8. http://dx.doi.org/10.1055/s-0034-1371178.
4. Schneider MD, Sarrazin C. 2014. Antiviral therapy of hepatitis C in 2014: Do we need resistance testing? Antiviral Res 105:64-71. http://dx.doi.org/10.1016/j.antiviral.2014.02.011.
5. Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S, Takemoto D, Dondero E, Kwong AD, Picchio G, Kieffer TL. 2013. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol 87:1544-1553. http://dx.doi.org/10.1128/JVI.02294-12.
6. Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, Pfeiffer T, Tigges AM, Adiwijaya BS, Lin C, Kwong AD, Kieffer TL. 2008. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis 198:800-807. http://dx.doi.org/10.1086/591141.
7. Besse B, Coste-Burel M, Bourgeois N, Feray C, Imbert-Marcille BM, Andre-Garnier E. 2012. Genotyping and resistance profile of hepatitis C (HCV) genotypes 1- 6 by sequencing the NS3 protease region using a single optimized sensitive method. J Virol Methods 185:94-100. http://dx.doi.org/10.1016/j.jviromet.2012.06.011.
8. Gaudieri S, Rauch A, Pfafferott K, Barnes E, Cheng W, McCaughan G, Shackel N, Jeffrey GP, Mollison L, Baker R, Furrer H, Gunthard HF, Freitas E, Humphreys I, Klenerman P, Mallal S, James I, Roberts S, Nolan D, Lucas M. 2009. Hepatitis C virus drug resistance and immunedriven adaptations: relevance to new antiviral therapy. Hepatology 49: 1069-1082. http://dx.doi.org/10.1002/hep.22773.
9. Palanisamy N, Danielsson A, Kokkula C, Yin H, Bondeson K, Wesslen L, Duberg AS, Lennerstrand J. 2013. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in hepatitis C virus genotypes 1a, 2b and 3a. Antiviral Res 99:12-17. http://dx.doi.org/10.1016/j.antiviral.2013.04.018.
10. Paolucci S, Fiorina L, Piralla A, Gulminetti R, Novati S, Barbarini G, Sacchi P, Gatti M, Dossena L, Baldanti F. 2012. Naturally occurring mutations to HCV protease inhibitors in treatment-naive patients. Virol J 9:245. http://dx.doi.org/10.1186/1743-422X-9-245.
11. Vallet S, Viron F, Henquell C, Le Guillou-Guillemette H, Lagathu G, Abravanel F, Trimoulet P, Soussan P, Schvoerer E, Rosenberg A, Gouriou S, Colson P, Izopet J, Payan C, ANRS AC11 HCV Group. 2011. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5. Antivir Ther 16:1093-1102. http://dx.doi.org/10.3851/IMP1900.
12. Barnard RJ, Howe JA, Ogert RA, Zeuzem S, Poordad F, Gordon SC, Ralston R, Tong X, Sniukiene V, Strizki J, Ryan D, Long J, Qiu P, Brass CA, Albrecht J, Burroughs M, Vuocolo S, Hazuda DJ. 2013. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology 444:329-336. http://dx.doi.org/10.1016/j.virol.2013.06.029.
13. De Meyer S, Dierynck I, Ghys A, Beumont M, Daems B, Van Baelen B, Sullivan JC, Bartels DJ, Kieffer TL, Zeuzem S, Picchio G. 2012. Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial. Hepatology 56:2106-2115. http://dx.doi.org/10.1002/hep.25962.
14. Hézode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, de Ledinghen V, Poynard T, Samuel D, Bourliere M, Zarski JP, Raabe JJ, Alric L, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Metivier S, Tran A, Serfaty L, Abergel A, Causse X, Di Martino V, Guyader D, Lucidarme D, Grando-Lemaire V, Hillon P, Feray C, Dao T, Cacoub P, Rosa I, Attali P, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP, CUPIC Study Group. 2013. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J Hepatol 59:434-441. http://dx.doi.org/10.1016/j.jhep.2013.04.035.
15. Leroy V, Serfaty L, Bourliere M, Bronowicki JP, Delasalle P, Pariente A, Pol S, Zoulim F, Pageaux GP, French Association for the Study of the Liver. 2012. Protease inhibitor-based triple therapy in chronic hepatitis C: Guidelines by the French Association for the Study of the Liver. Liver Int 32:1477-1492. http://dx.doi.org/10.1111/j.1478-3231.2012.02856.x.
16. Vallet S, Larrat S, Laperche S, Le Guillou-Guillemette H, Legrand-Abravanel F, Bouchardeau F, Pivert A, Henquell C, Mirand A, Andre-Garnier E, Giordanengo V, Lagathu G, Thibault V, Scholtes C, Schvoerer E, Gaudy-Graffin C, Maylin S, Trimoulet P, Brochot E, Hantz S, Gozlan J, Roque-Afonso AM, Soussan P, Plantier JC, Charpentier C, Chevaliez S, Colson P, Mackiewicz V, Aguilera L, Rosec S, Gouriou S, Magnat N, Lunel-Fabiani F, Izopet J, Morand P, Payan C, Pawlotsky JM. 2013. Multicenter quality control of hepatitis C virus protease inhibitor resistance genotyping. J Clin Microbiol 51:1428-1433.
17. Kieffer TL, De Meyer S, Bartels DJ, Sullivan JC, Zhang EZ, Tigges A, Dierynck I, Spanks J, Dorrian J, Jiang M, Adiwijaya B, Ghys A, Beumont M, Kauffman RS, Adda N, Jacobson IM, Sherman KE, Zeuzem S, Kwong AD, Picchio G. 2012. Hepatitis C viral evolution in genotype 1 treatment-naive and treatment-experienced patients receiving telaprevirbased therapy in clinical trials. PLoS One 7:e34372. http://dx.doi.org/10.1371/journal.pone.0034372.
18. Lenz O, Verbinnen T, Lin TI, Vijgen L, Cummings MD, Lindberg J, Berke JM, Dehertogh P, Fransen E, Scholliers A, Vermeiren K, Ivens T, Raboisson P, Edlund M, Storm S, Vrang L, de Kock H, Fanning GC, Simmen KA. 2010. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 54: 1878-1887. http://dx.doi.org/10.1128/AAC.01452-09.
19. Susser S, Welsch C, Wang Y, Zettler M, Domingues FS, Karey U, Hughes E, Ralston R, Tong X, Herrmann E, Zeuzem S, Sarrazin C. 2009. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 50:1709-1718. http://dx.doi.org/10.1002/hep.23192.
20. Katoh K, Misawa K, Kuma K, Miyata T. 2002. MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. Nucleic Acids Res 30:3059-3066. http://dx.doi.org/10.1093/nar/gkf436.
21. Katoh K, Standley DM. 2013. MAFFT multiple sequence alignment software version 7: Improvements in performance and usability. Mol Biol Evol 30:772-780. http://dx.doi.org/10.1093/molbev/mst010.
22. Kuraku S, Zmasek CM, Nishimura O, Katoh K. 2013. aLeaves facilitates on-demand exploration of metazoan gene family trees on MAFFT sequence alignment server with enhanced interactivity. Nucleic Acids Res 41:W22-28. http://dx.doi.org/10.1093/nar/gkt389.
23. Han MV, Zmasek CM. 2009. phyloXML: XML for evolutionary biology and comparative genomics. BMC Bioinformatics 10:356. http://dx.doi.org/10.1186/1471-2105-10-356.
24. Wyles DL, Gutierrez JA. 2014. Importance of HCV genotype 1 subtypes for drug resistance and response to therapy. J Viral Hepat 21:229-240. http://dx.doi.org/10.1111/jvh.12230.
25. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, Moroz L, Craxi A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Scott J, Sinha R, Beumont-Mauviel M. 2014. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 384:403-413. http://dx.doi.org/10.1016/S0140-6736(14)60494-3.
26. Trimoulet P, Pinson P, Papuchon J, Foucher J, Vergniol J, Chermak F, Wittkop L, Castaing N, Merrouche W, Reigadas S, Molimard M, Kann M, Fleury H, de Ledinghen V. 2013. Dynamic and rapid changes in viral quasispecies by UDPS in chronic hepatitis C patients receiving telaprevir-based therapy. Antivir Ther 18:723-727. http://dx.doi.org/10.3851/IMP2632.